Lakefront Biotherapeutics (LKFT) Receivables (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Receivables of $63.3 million for Q1 2026, down 27.97% year-over-year from $87.8 million in Q1 2025, and up 4.68% quarter-over-quarter from $60.4 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Receivables (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Receivables for 13 consecutive years, with $63.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 27.97% year-over-year to $63.3 million; the TTM figure through Mar 2026 stood at $63.3 million (down 27.97% YoY), while the FY2025 annual figure was $60.4 million, down 1.88% from the prior year.
- Receivables improved to $63.3 million in Q1 2026 per LKFT's latest filing, from $60.4 million in the prior quarter.
- Across five years, Receivables topped out at $100.0 million in Q1 2024 and bottomed at $36.2 million in Q4 2023.
- Historically, Receivables has averaged $75.8 million across 5 years, with a median of $79.5 million in 2023.
- Annual changes were most pronounced in 2022 — Receivables sank 65.24% — and 2024, when it jumped 70.13%.
- Lakefront Biotherapeutics' Receivables stood at $49.3 million in 2022, then declined by 26.54% to $36.2 million in 2023, then surged by 70.13% to $61.6 million in 2024, then retreated by 1.88% to $60.4 million in 2025, then grew by 4.68% to $63.3 million in 2026.
- Business Quant data shows LKFT's Receivables at $63.3 million in Q1 2026, $60.4 million in Q4 2025, and $90.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Lakefront Biotherapeutics | 1.81 Bn | -1.68 Bn | 1.97 Mn | 63.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.26 Mn |
| Dec 31, 2025 | 60.43 Mn |
| Sep 30, 2025 | 90.80 Mn |
| Jun 30, 2025 | 99.43 Mn |
| Mar 31, 2025 | 87.82 Mn |
| Dec 31, 2024 | 61.59 Mn |
| Sep 30, 2024 | 95.79 Mn |
| Mar 31, 2024 | 100.00 Mn |
| Dec 31, 2023 | 36.20 Mn |
| Sep 30, 2023 | 79.52 Mn |
| Mar 31, 2023 | 72.52 Mn |
| Dec 31, 2022 | 49.28 Mn |
| Mar 31, 2022 | 88.13 Mn |
| Dec 31, 2021 | 141.78 Mn |
| Jun 30, 2021 | 136.81 Mn |
| Dec 31, 2020 | 193.13 Mn |
| Jun 30, 2020 | 49.77 Mn |
| Mar 31, 2020 | 54.29 Mn |
| Dec 31, 2019 | 75.40 Mn |
| Sep 30, 2019 | 47.17 Mn |